JG26

JG26 is an ADAM inhibitor with IC₅₀ values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC₅₀ value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases^{[1][2][3][4][5][6]}. In Vitro: JG26 (5-25 µM; 24-48 h) has no significant effect on the viability of Calu-3 cells (CC₅₀: >25 µM) and increases the expression of ACE2 on the surface of Calu-3 cells^[1].
JG26 (25 µM) can significantly reduce the infection of SARS-CoV-2 in Calu-3 cells, with LR values of 1.44 and 2.37, respectively^[1].
JG26 (10 µM; 24 h) can reduce the shedding of NKG2D ligands in Hodgkin lymphoma cell lines^[2].
JG26 (125 nM-10 µM; 24 h) can inhibit the cleavage of CD23 and the release of its soluble form in HEK293 cells^[3].
JG26 (25 nM; 2 h) can effectively reduce the permeability of HUVECs and tumor cell adhesion induced by EMT-HCT116 exosomes^[4].
JG26 (1 μM; 30 min) inhibits AngII-induced extracellular collagen accumulation in vascular smooth muscle cells (VSMCs)^[5].
In Vivo: JG26 (3 mg/kg; i.v.) inhibits tumor metastasis in the orthotropic metastasis model of colorectal cancer (CRC) mice^[4].